- Home
- KALU vs EWTX Comparison
KALU vs EWTX Comparison
Compare KALU & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- EWTX
- Stock Information
- Founded
- KALU 1946
- EWTX 2017
- Country
- KALU United States
- EWTX United States
- Employees
- KALU 3900
- EWTX N/A
- Industry
- KALU Metal Fabrications
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- EWTX Health Care
- Exchange
- KALU Nasdaq
- EWTX Nasdaq
- Market Cap
- KALU 1.5B
- EWTX 1.6B
- IPO Year
- KALU 1991
- EWTX 2021
- Fundamental
- Price
- KALU $93.91
- EWTX $23.60
- Analyst Decision
- KALU Buy
- EWTX Buy
- Analyst Count
- KALU 3
- EWTX 10
- Target Price
- KALU $95.67
- EWTX $37.30
- AVG Volume (30 Days)
- KALU 169.2K
- EWTX 1.3M
- Earning Date
- KALU 10-22-2025
- EWTX 11-06-2025
- Dividend Yield
- KALU 3.36%
- EWTX N/A
- EPS Growth
- KALU 58.01
- EWTX N/A
- EPS
- KALU 5.17
- EWTX N/A
- Revenue
- KALU $3,209,400,000.00
- EWTX N/A
- Revenue This Year
- KALU $12.83
- EWTX N/A
- Revenue Next Year
- KALU $12.98
- EWTX N/A
- P/E Ratio
- KALU $17.75
- EWTX N/A
- Revenue Growth
- KALU 7.69
- EWTX N/A
- 52 Week Low
- KALU $46.81
- EWTX $10.60
- 52 Week High
- KALU $97.63
- EWTX $35.50
- Technical
- Relative Strength Index (RSI)
- KALU 58.56
- EWTX 75.75
- Support Level
- KALU $88.58
- EWTX $21.72
- Resistance Level
- KALU $92.39
- EWTX $23.36
- Average True Range (ATR)
- KALU 3.11
- EWTX 1.50
- MACD
- KALU -0.62
- EWTX 0.32
- Stochastic Oscillator
- KALU 56.18
- EWTX 95.34
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.